Compositions and methods for diagnosing and treating kidney disorders in a feline
First Claim
1. A method of diagnosing the existence of a kidney disorder in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of lumican;
- collagen alpha 1(III) chain, variant 12;
decorin;
secreted frizzled-related protein 2;
retinol binding protein 5;
MMP-2;
MMP-7; and
MMP-19, in a biological sample from the feline,comparing the level of expression of the one or more biomarkers in the biological sample from the feline to a control value, anddiagnosing the existence of the kidney disorder in the feline, wherein differences in expression of the one or more biomarkers in the sample relative to the control value for expression in a sample from a normal animal indicate the existence of a kidney disorder,wherein the level of expression of the one or more biomarkers is determined by measuring gene expression of the one or more biomarkers using a DNA microarray comprising one or more oligonucleotides complementary to mRNA or cDNA corresponding to the one or more biomarkers to be measured, andwherein the oligonucleotides in the DNA microarray comprise one or more probes comprising sequences selected from one or more of SEQ ID NOS. 1-8.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides a method of diagnosing the existence of a kidney disorder in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of lumican; collagen alpha 1 (111) chain, variant 12; decorin; secreted frizzled-related protein 2; retinol binding protein 5; MMP-2; MMP-7; and MMP-19, in a biological sample from the feline, wherein differences in expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal animal indicate the existence of a kidney disorder; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
-
Citations
14 Claims
-
1. A method of diagnosing the existence of a kidney disorder in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of lumican;
- collagen alpha 1(III) chain, variant 12;
decorin;
secreted frizzled-related protein 2;
retinol binding protein 5;
MMP-2;
MMP-7; and
MMP-19, in a biological sample from the feline,comparing the level of expression of the one or more biomarkers in the biological sample from the feline to a control value, and diagnosing the existence of the kidney disorder in the feline, wherein differences in expression of the one or more biomarkers in the sample relative to the control value for expression in a sample from a normal animal indicate the existence of a kidney disorder, wherein the level of expression of the one or more biomarkers is determined by measuring gene expression of the one or more biomarkers using a DNA microarray comprising one or more oligonucleotides complementary to mRNA or cDNA corresponding to the one or more biomarkers to be measured, and wherein the oligonucleotides in the DNA microarray comprise one or more probes comprising sequences selected from one or more of SEQ ID NOS. 1-8. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
- collagen alpha 1(III) chain, variant 12;
Specification